Drug Shortage Report for DAXAS
| Report ID | 262993 |
| Drug Identification Number | 02359456 |
| Brand name | DAXAS |
| Common or Proper name | roflumilast |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | ROFLUMILAST |
| Strength(s) | 500MCG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 30 tablets |
| ATC code | R03DX |
| ATC description | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-09-08 |
| Actual start date | |
| Estimated end date | 2025-09-22 |
| Actual end date | 2025-08-11 |
| Shortage status | Avoided shortage |
| Updated date | 2025-08-11 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-08-11 | French | Compare |
| v3 | 2025-08-11 | English | Compare |
| v2 | 2025-07-17 | French | Compare |
| v1 | 2025-07-17 | English | Compare |
Showing 1 to 4 of 4